Drug prices are kept high in US by protection and price negotiations, study findsBMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i4640 (Published 23 August 2016) Cite this as: BMJ 2016;354:i4640
- Michael McCarthy
The high cost of prescription drugs in the United States is due in large part to the monopoly power granted to manufacturers through the drug and patent approval processes, together with restrictions that limit the ability of payers to negotiate prices, researchers have concluded in a study in JAMA.1
Currently, per capita prescription drug spending in the US is the highest in the world, reaching $858 (£660; €760) in 2013, more than twice the average of $400 in 19 other industrialized nations.
In the new study, Aaron S Kesselheim, of Harvard Medical …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial